412300-33-5 Usage
Explanation
The compound is composed of 20 carbon atoms, 16 hydrogen atoms, and 3 oxygen atoms.
Explanation
It belongs to a class of organic compounds that contain a benzene ring fused to a furan ring.
Explanation
The compound has a benzofuran ring, which is a fusion of a benzene ring and a furan ring. A benzyloxy group is attached to the 6th position of the benzofuran ring, and a ketone group is present at the 1st position.
Explanation
The compound is a derivative of a ketone, which is a carbonyl compound with a C=O double bond.
Explanation
It is commonly used in the synthesis of various organic compounds and is also utilized in pharmaceutical research for the development of new drugs.
6. Potential Pharmacological Activities
Explanation
The compound may have pharmacological properties, making it a candidate for further research and development in the field of drug discovery.
7. Building Block for Synthesis of Biologically Active Molecules
Explanation
Due to its unique chemical structure, the compound can be used as a starting material for the synthesis of other biologically active molecules with potential therapeutic applications.
8. Interest in Drug Development
Explanation
The compound's chemical structure and properties make it a promising candidate for the development of new drugs and pharmaceuticals, particularly in the context of its potential pharmacological activities and utility as a building block for other biologically active molecules.
Class
Benzofuran compounds
Structure
Benzofuran ring with a benzyloxy group at the 6-position and a ketone group at the 1-position
Type
Ketone derivative
Application
Organic synthesis and pharmaceutical research
Check Digit Verification of cas no
The CAS Registry Mumber 412300-33-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,1,2,3,0 and 0 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 412300-33:
(8*4)+(7*1)+(6*2)+(5*3)+(4*0)+(3*0)+(2*3)+(1*3)=75
75 % 10 = 5
So 412300-33-5 is a valid CAS Registry Number.
412300-33-5Relevant articles and documents
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy
Miller, Michael M.,Banville, Jacques,Friends, Todd J.,Gagnon, Mark,Hangeland, Jon J.,Lavallée, Jean-Fran?ois,Martel, Alain,O'Grady, Harold,Rémillard, Roger,Ruediger, Edward,Tremblay, Fran?ois,Posy, Shana L.,Allegretto, Nick J.,Guarino, Victor R.,Harden, David G.,Harper, Timothy W.,Hartl, Karen,Josephs, Jonathan,Malmstrom, Sarah,Watson, Carol,Yang, Yanou,Zhang, Ge,Wong, Pancras,Yang, Jing,Bouvier, Michel,Seiffert, Dietmar A.,Wexler, Ruth R.,Lawrence, R. Michael,Priestley, E. Scott,Marinier, Anne
, p. 7400 - 7416 (2019/08/26)
In an effort to identify novel antithrombotics, we have investigated protease-activated receptor 4 (PAR4) antagonism by developing and evaluating a tool compound, UDM-001651, in a monkey thrombosis model. Beginning with a high-throughput screening hit, we identified an imidazothiadiazole-based PAR4 antagonist chemotype. Detailed structure-activity relationship studies enabled optimization to a potent, selective, and orally bioavailable PAR4 antagonist, UDM-001651. UDM-001651 was evaluated in a monkey thrombosis model and shown to have robust antithrombotic efficacy and no prolongation of kidney bleeding time. This combination of excellent efficacy and safety margin strongly validates PAR4 antagonism as a promising antithrombotic mechanism.
NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
-
Page/Page column 27; 41, (2015/06/25)
The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.
